These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26873053)

  • 21. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
    Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
    Malm M; Heinimäki S; Vesikari T; Blazevic V
    Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.
    Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y
    J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies.
    Panasiuk M; Zimmer K; Czarnota A; Grzyb K; Narajczyk M; Peszyńska-Sularz G; Żołędowska S; Nidzworski D; Hovhannisyan L; Gromadzka B
    Microb Cell Fact; 2021 Sep; 20(1):186. PubMed ID: 34560881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.
    Atmar RL; Baehner F; Cramer JP; Lloyd E; Sherwood J; Borkowski A; Mendelman PM;
    J Infect Dis; 2019 Jul; 220(4):603-614. PubMed ID: 31001633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.
    Velasquez LS; Hjelm BE; Arntzen CJ; Herbst-Kralovetz MM
    Clin Vaccine Immunol; 2010 Dec; 17(12):1850-8. PubMed ID: 20962211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.
    Guerrero RA; Ball JM; Krater SS; Pacheco SE; Clements JD; Estes MK
    J Virol; 2001 Oct; 75(20):9713-22. PubMed ID: 11559804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice.
    Hou W; Lv L; Wang Y; Xing M; Guo Y; Xie D; Wei X; Zhang X; Liu H; Ren J; Zhou D
    Front Immunol; 2022; 13():906275. PubMed ID: 35711416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    Lindesmith LC; Mallory ML; Jones TA; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    J Infect Dis; 2017 Mar; 215(6):984-991. PubMed ID: 28453838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.
    Yao Q; Vuong V; Li M; Compans RW
    Vaccine; 2002 Jun; 20(19-20):2537-45. PubMed ID: 12057610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune responses against norovirus GII.4 virus-like particles in mice.
    Ushijima H; Machida S; Nomura A; Khamrin P; Tran DN; Nomura H; Hayakawa S
    Acta Virol; 2016; 60(4):339-346. PubMed ID: 27928912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.
    LoBue AD; Lindesmith L; Yount B; Harrington PR; Thompson JM; Johnston RE; Moe CL; Baric RS
    Vaccine; 2006 Jun; 24(24):5220-34. PubMed ID: 16650512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.
    Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D;
    Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
    Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
    PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.